Literature DB >> 9929286

A fuzzy classification system to predict renal artery restenosis after angioplasty.

I Cherrak1, M C Jaulent, P Degoulet.   

Abstract

Percutaneous transluminal angioplasty (PTRA) has emerged as a promising treatment for patients with renovascular hypertension. However, the benefit of this procedure is hampered by restenosis that frequently occurs within around 6 months after a successful angioplasty. This paper presents a fuzzy classification system based on a fuzzy pattern matching model that is being developed to evaluate the risk of short-term restenosis. First, identified classes are represented by fuzzy prototypes that take into account the imprecision of the criteria. Second, the system is applied to angiographic features of given stenoses and provides the membership degree of these stenosis to the two classes "short term restenosis" or "no restenosis". The fuzzy classifier's performances have been tested on twenty two patients who underwent balloon angioplasty in the context of a French multicenter randomized trial EMMA. With the fuzzy classifier, restenosis were predicted prospectively with 100% while its sensitivity is about 73%. The fuzzy classification system is expected to become a reliable tool to predict PTRA outcomes.

Entities:  

Mesh:

Year:  1998        PMID: 9929286      PMCID: PMC2232174     

Source DB:  PubMed          Journal:  Proc AMIA Symp        ISSN: 1531-605X


  10 in total

1.  Technique of percutaneous transluminal angioplasty with the Grüntzig ballon catheter.

Authors:  A Grüntzig; D A Kumpe
Journal:  AJR Am J Roentgenol       Date:  1979-04       Impact factor: 3.959

2.  Guidelines for percutaneous transluminal coronary angioplasty. A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty).

Authors:  T J Ryan; W B Bauman; J W Kennedy; D J Kereiakes; S B King; B D McCallister; S C Smith; D J Ullyot
Journal:  Circulation       Date:  1993-12       Impact factor: 29.690

3.  Description and representation of segmented renal arteries from angiograms.

Authors:  M C Jaulent; J F Paul; P Boittin; P Degoulet
Journal:  Proc Annu Symp Comput Appl Med Care       Date:  1993

4.  Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group.

Authors:  P F Plouin; G Chatellier; B Darné; A Raynaud
Journal:  Hypertension       Date:  1998-03       Impact factor: 10.190

5.  Automatic stenosis detection and quantification in renal arteriography.

Authors:  I Cherrak; J F Paul; M C Jaulent; G Chatellier; P F Plouin; J C Gaux; P Degoulet
Journal:  Proc AMIA Annu Fall Symp       Date:  1997

6.  Angiographic predictors of new coronary occlusions.

Authors:  M K Pétursson; E H Jónmundsson; A Brekkan; T Hardarson
Journal:  Am Heart J       Date:  1995-03       Impact factor: 4.749

7.  Restenosis after a first percutaneous transluminal renal angioplasty.

Authors:  P F Plouin; B Darné; G Chatellier; I Pannier; C Battaglia; A Raynaud; M Azizi
Journal:  Hypertension       Date:  1993-01       Impact factor: 10.190

Review 8.  [Therapeutic approach in arterial hypertension with renal artery stenosis].

Authors:  P F Plouin; G Chatellier; C Fumeron; C Battaglia; X Girerd; M Azizi
Journal:  Presse Med       Date:  1994-10-15       Impact factor: 1.228

9.  Percutaneous transluminal renal angioplasty in management of atherosclerotic renovascular hypertension: results in 100 patients.

Authors:  V J Canzanello; V G Millan; J E Spiegel; P S Ponce; R I Kopelman; N E Madias
Journal:  Hypertension       Date:  1989-02       Impact factor: 10.190

10.  Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience.

Authors:  K Tan; N Sulke; N Taub; E Sowton
Journal:  J Am Coll Cardiol       Date:  1995-03-15       Impact factor: 24.094

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.